Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.67
(
-0.98%
)
Bitcoin
74,303.38
(
0.49%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: DewDiligence post# 143379

Wednesday, 06/06/2012 3:52:33 PM

Wednesday, June 06, 2012 3:52:33 PM

Post# of 257253
Intuitive Surgical (ISRG +2.2%) should be bought , albeit selectively, says William Blair. The firm recommends using the recent weakness to pick it up. Its channel checks indicate the outlook for robotic surgery has never been stronger, however Zytiga drug approval is likely years away. The firm maintains an Outperform rating



silly question...why Zytinga reference in above blurb on ISRG?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now